James Cavanaugh Net Worth

James Cavanaugh biography

Dr. James H. Cavanaugh Ph.D. serves as Independent Director of the Company. He has served as a member of our Board since January 2016. Dr. Cavanaugh is a Senior Advisor to HealthCare Ventures, where prior he had been a managing director since 1989. He was previously President of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. Dr. Cavanaugh had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He has been a board member of a number of private and public pharmaceutical and biotechnology companies and was Chairman of The Shire Pharmaceutical Group, plc. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the president's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his Master's and Doctorate degrees.

How old is James Cavanaugh?

James Cavanaugh is 82, he's been the Independent Director of Leap Therapeutics Inc since 2016. There are no older and 10 younger executives at Leap Therapeutics Inc.

What's James Cavanaugh's mailing address?

James's mailing address filed with the SEC is C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE, MA, 02141.

Insiders trading at Leap Therapeutics Inc

Over the last 8 years, insiders at Leap Therapeutics Inc have traded over $0 worth of Leap Therapeutics Inc stock and bought 10,810,588 units worth $40,517,079 . The most active insiders traders include Advisors Llcperceptive Life..., Christopher Mirabelli und Ltd. Bei Gene,. On average, Leap Therapeutics Inc executives and independent directors trade stock every 142 days with the average trade being worth of $1,990,710. The most recent stock trade was executed by Christopher Mirabelli on 26 January 2024, trading 5,000 units of LPTX stock currently worth $13,850.

What does Leap Therapeutics Inc do?

leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.

Leap Therapeutics Inc executives and stock owners

Leap Therapeutics Inc executives and other stock owners filed with the SEC include:

• Douglas Onsi,
  President, Chief Executive Officer, Director
• Augustine Lawlor,
  Chief Operating Officer
• Christopher Mirabelli,
  Chairman of the Board
• Cynthia Sirard,
  Chief Medical Officer
• Mark O'Mahony,
  Chief Manufacturing Officer
• Nissim Mashiach,
  Independent Director
• Joseph Loscalzo,
  Independent Director
• William Li,
  Independent Director
• Thomas Dietz,
  Lead Independent Director
• James Cavanaugh,
  Independent Director
• Monica Bertagnolli,
  Independent Director
• John W Littlechild,
  Director
• Ventures Ix, L.P.Healthcare...,
  
• Harold R Werner,
  10% owner
• Lilly & Co Eli,
  10% owner
• Patricia A. Martin,
  Director
• Christian M Richard,
  Director
• Richard Schilsky,
  Director
• Advisors Llcperceptive Life...,
  
• Ventures Viii, L.P.Health C...,
  
• Jason Baum,
  Chief Scientific Officer
• Christine Granfield,
  VP, Head of Reg Affairs/Qual
• Ltd. Bei Gene,,
  10% owner